Buprenorphine and naloxone compared with methadone treatment in pregnancy

Obstetrics and Gynecology

Volumn 125, Issue 2, 2015, Pages 363-368

  Wiegand, Samantha L ^a   Stringer, Elizabeth M ^a   Stuebe, Alison M ^a   Jones, Hendree ^a   Seashore, Carl ^a   Thorp, John ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; ILLICIT DRUG; METHADONE; MORPHINE; NALOXONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADDICTION; ADULT; APGAR SCORE; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; DELIVERY; DRUG USE; FEMALE; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MATERNAL SMOKING; METHADONE TREATMENT; MOTHER; NEWBORN; NEWBORN INTENSIVE CARE; PAIN; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; ADVERSE EFFECTS; COMPARATIVE STUDY; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84922437812     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000640     Document Type: Article

References (20)

1. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998; 25: 139-51
2. Committee on Health Care for Underserved Women, American Society of Addiction Medicine. Opioid abuse, dependence, and addiction in pregnancy. Committee Opinion No. 524. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 119: 1070-6
3. Center for Substance Abuse Treatment. Medication assisted treatment for opioid addiction during pregnancy. In: SAHMSA/CSAT treatment improvement protocols. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2008
4. Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012; 24: 252-8
5. Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008; 35: 245-59
6. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569-80
7. Ariëns EJ. Intrinsic activity: partial agonists and partial antagonists. J Cardiovasc Pharmacol 1983; 5(suppl 1): S8-15
8. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003; 70(2 suppl): S87-101
9. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment opioid-dependent pregnant women: a comprehensive review. Addiction 2012; 107(suppl 1): 5-27
10. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-Tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349: 949-58
11. Johnson RE, McCagh JC. Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep 2000; 2: 519-26
12. Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine+ naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict 2013; 22: 252-4
13. Lund IO, Fischer G, Welle-Strand GK, O'Grady KE, Debelak K, Morrone WR, et al A Comparison of Buprenorphine+ Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. Subst Abuse 2013; 7: 61-74
14. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2: 141-58
15. Metz V, Jagsch R, Ebner N, Würlz J, Pribasniq A, Aschauer C, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol 2011; 26: 412-21
16. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Crisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10
17. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-31
18. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010; 125: e214-24
19. Maguire D, Cline GC, Parnell L, Tai CY. Validation of the Finnegan neonatal abstinence syndrome tool-short form. Adv Neonatal Care 2013; 13: 430-7
20. Lucas K, Knobel RB. Implementing practice guidelines and education to improve care of infants with neonatal abstinence syndrome. Adv Neonatal Care 2012; 12: 40-5